Clinical trials: Mucosal Melanoma
Mucosal Melanoma
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.
- Trial name
- NCT05384496
- Testing
- Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma
- Trial name
- NCT03865212
- Testing
- Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Mucosal Melanoma
Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib tablet (Inlyta®) as neoadjuvant therapy for localized…
- Trial name
- NCT04180995
- Testing
- TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma, Melanoma (Skin)
Atypical MOLes and Melanoma Early Detection Study (MoleMed)
This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms.
- Conditions
- Melanoma, Melanoma (Skin), Moles, Nevus
- Trial name
- MoleMed (NCT04353050)
- Testing
- Non-invasive adhesive system (patch)
- Where
- 2 sites in Russia
- Volunteers
- 350 people
- Sponsor
- Russian Academy of Medical Sciences
Acral Melanoma, Mucosal Melanoma
Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
This trial is a multicenter, single arm study of efficacy of vactosertib in combination with pembrolizumab in advanced acral or mucosal melanoma patients progressed prior treatment including immunotherapy or targeted therapy and…
- Trial name
- NCT05436990
- Testing
- Pembrolizumab, Vactosertib
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Yonsei University
Cutaneous Melanoma, Mucosal Melanoma
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits.
- Trial name
- Neo IRENIE (NCT06999980)
- Testing
- Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg
- Where
- Australia
- Volunteers
- 494 people
- Sponsor
- Melanoma Institute Australia
Advanced Melanoma
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of…
- Trial name
- NCT05549297
- Testing
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 540 people
- Sponsor
- Immunocore Ltd
Melanoma
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.
- Trial name
- NCT04979585
- Testing
- Camrelizumab, Anlotinib, nab-Paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Di Wu
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Mucosal Melanoma, Recurrent Melanoma
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow.
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT01166126
- Testing
- temsirolimus, selumetinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Mucosal Melanoma
Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
This study is a prospective, multicenter, single arm, open label study aimed at evaluating the efficacy and safety of the combination of Carilizumab, Apatinib Mesylate, and first-line radiotherapy for advanced mucosal melanoma.
- Trial name
- NCT07236528
- Testing
- Carilizumab and Apatinib
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Melanoma
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF…
- Trial name
- NCT04489433
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Mucosal Melanoma
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
This study was a phase IB, single-center, open-label, two part(part A involved dose reduction, and part B involved cohort expansion) clinical trial evaluating the safety and clinical activity of AK104 or AK112 in combination with…
- Conditions
- Melanoma, Mucosal Melanoma, Metastatic Melanoma
- Trial name
- NCT06424626
- Testing
- AK104+Axitinib, AK112+Axitinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Melanoma
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and…
- Trial name
- NCT00881049
- Testing
- Imatinib (Gleevec)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Cervical Carcinoma, Esophageal Carcinoma
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
This randomized phase II trial studies how well nivolumab or expectant observation following ipilimumab, nivolumab, and surgery work in treating patients with high-risk mucosal melanoma that is restricted to the site of origin…
- Conditions
- Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck
- Trial name
- NCT03220009
- Testing
- Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Acral Melanoma, Advanced Cutaneous Melanoma
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
This phase II trial tests the safety and effectiveness of giving ipilimumab and nivolumab in the morning compared to other times of day in treating patients with melanoma that is stage IV or that cannot be removed by surgery…
- Conditions
- Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT07155317
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Emory University
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Melanoma, Unresectable Melanoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes [TIL]) after receiving a lymphodepleting chemotherapy regimen and before…
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma
- Trial name
- NCT05628883
- Testing
- TBio-4101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Mucosal Melanoma
Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma
This is a phase II, open, single-center study to explore the efficacy and safety of Envafolimab combined with recombinant human endostatin, temozolomide and cisplatin in the treatment of mucosal melanin.
- Trial name
- NCT06041724
- Testing
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- Volunteers
- 46 people
- Sponsor
- Fudan University